
French BioTech developer SeaBeLife raises €2 million to tackle dry AMD and severe acute hepatitis
Roscoff-based SeaBeLife, a BioTech company developing innovative drug candidates intended to block cellular necrosis, today announces a pre-Series A funding round worth €2 million. The financing was led by historical investor iXLife, alongside other …